Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 7/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5676166 | 0.88 | CHRM1 (0.42) | HPGDEPHX1NPC1RAB9AABL1 | |
| SCHEMBL1840539 | 0.85 | CHRM1 (0.56) | HPGDKMT2A | |
| SCHEMBL17684002 | 0.84 | EPHX1 (0.47) | HPGDEPHX1PTPN2PTPN1PTPN6 | |
| SCHEMBL1840745 | 0.84 | CHRM1 (0.39) | HPGDNPC1RAB9AKMT2AEPHX2 | |
| SCHEMBL5674155 | 0.83 | EPHX2 (0.54) | HPGDEPHX1STSKMT2AEPHX2 | |
| SCHEMBL1840744 | 0.81 | CHRM1 (0.47) | HPGDNPC1RAB9AKMT2A | |
| SCHEMBL5678750 | 0.81 | CHRM1 (0.44) | HPGDNPC1RAB9AKMT2A | |
| SCHEMBL15241797 | 0.79 | FPR2 (0.38) | — | |
| SCHEMBL2926865 | 0.77 | HPGD (0.51) | HPGDEPHX1PTPN2PTPN1PTPN6 | |
| SCHEMBL5102682 | 0.77 | HDAC8 (0.39) | HPGDEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1616859-B1 | Substituted cyclohexyl carboxylic acid compounds | SEIKAGAKU KOGYO CO LTD (JP) | 2013-09-04 | — | — | EP | claimed |
| EP-1616859-A1 | Substituted cyclohexyl carboxylic acid compounds | SEIKAGAKU CORPORATION (JP) | 2006-01-18 | — | — | EP | claimed |
| EP-1616859-B1 | Substituted cyclohexyl carboxylic acid compounds | SEIKAGAKU KOGYO CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-7342027-B2 | 1-phenylpiperidin-3-one derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2008-03-11 | — | — | US | disclosed |
| EP-1008592-B1 | Cyclic amide derivatives which inhibit cathepsin K | SEIKAGAKU KOGYO CO LTD (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1008592-B1 | Cyclic amide derivatives which inhibit cathepsin K | SEIKAGAKU KOGYO CO LTD (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1619189-A1 | N-(3-acyl-2-hydroxyalkyl) cycloalkyl amide derivatives | SEIKAGAKU CORPORATION (JP) | 2006-01-25 | — | — | EP | disclosed |
| EP-1616867-A1 | Hydroxycarboxylic acid derivatives | SEIKAGAKU CORPORATION (JP) | 2006-01-18 | — | — | EP | disclosed |
| EP-1616859-A1 | Substituted cyclohexyl carboxylic acid compounds | SEIKAGAKU CORPORATION (JP) | 2006-01-18 | — | — | EP | disclosed |
| US-20050234057-A1 | 1-Phenylpiperidin-3-one derivatives and processes for the preparation thereof | DONG-A PHARMACEUTICAL CO., LTD. (KR) | 2005-10-20 | — | — | US | disclosed |
| WO-2004011457-A1 | 1-PHENYLPIPERIDIN-3-ONE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2004-02-05 | — | — | WO | disclosed |
| US-6117870-A | USEFUL AS THERAPEUTIC DRUG OR PREVENTIVE DRUG OF ARTHRITIS AND RHEUMATISM DUE TO INCREASE OF BONE RESORPTION IN ADDITION TO BONE DISEASES SUCH AS OSTEOPOROSIS, HYPERCALCEMIA, AND PAGET'S DISEASE | FUJIREBIO KABUSHIKI KAISHA (JP) | 2000-09-12 | — | — | US | disclosed |
| EP-1008592-A2 | Cyclic amide derivatives which inhibit cathepsin K | Fujirebio Kabushiki Kaisha (JP) | 2000-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234057-A1 | 1-Phenylpiperidin-3-one derivatives and processes for the preparation thereof | CTRL, PRCP, CLPP | HPGD 842/4885EPHX1 1720/4885PTPN2 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.